The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease
Open accessAbstract
Objective.: Small series suggest mycophenolate mofetil (MMF) is well tolerated and may be an effective therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD). We examined the tolerability and longitudinal changes in pulmonary physiology in a large and diverse cohort of patients with CTD-ILD treated with MMF. Methods.: We identified consecutive patients evaluated at our center between January 2008 and January 2011 and prescribed MMF for CTD-ILD. We assessed safety and tolerability of MMF and used longitudinal data analyses to examine changes in pulmonary physiology over time, before and after initiation of MMF. Results.: We identified 125 subjects treated with MMF for a median 897 days. MMF was discontinued in 13 subjects. MMF was associated with significant improvements in estimated percentage of predicted forced vital capacity (FVC%) from MMF initiation to 52, 104, and 156 weeks (4.9% ± 1.9%, p = 0.01; 6.1% ± 1.8%, p = 0.0008; and 7.3% ± 2.6%, p = 0.004, respectively); and in estimated percentage predicted diffusing capacity (DLCO%) from MMF initiation to 52 and 104 weeks (6.3% ± 2.8%, p = 0.02; 7.1% ± 2.8%, p = 0.01). In the subgroup without usual interstitial pneumonia (UIP)-pattern injury, MMF significantly improved FVC% and DLCO%, and in the subgroup with UIP-pattern injury, MMF was associated with stability in FVC% and DLCO%. Conclusion.: In a large diverse cohort of CTD-ILD, MMF was well tolerated and had a low rate of discontinuation. Treatment with MMF was associated with either stable or improved pulmonary physiology over a median 2.5 years of followup. MMF appears to be a promising therapy for the spectrum of CTD-ILD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Hoyles, R. K., Ellis, R. W., Wellsbury, J., Lees, B., Newlands, P., Goh, N. S. L., Roberts, C., Desai, S., Herrick, A. L., McHugh, N. J., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22204 · Cited by 732
Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Roth, M. D., Furst, D. E., Silver, R. M., Goldin, J., Arriola, E., Strange, C., Bolster, M. B., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200702-326oc · Cited by 464
Connective Tissue Disease-Associated Interstitial Lung Disease
Fischer, A., West, S. G., Swigris, J. J., Brown, K. K., & du Bois, R. M. (2010) · Chest · doi:10.1378/chest.10-0194 · Cited by 303
Self-citationLiossis, S. N. C., Bounas, A., & Andonopoulos, A. P. (2006) · Rheumatology · doi:10.1093/rheumatology/kei211 · Cited by 179
Saketkoo, L. A., & Espinoza, L. R. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31818d094b · Cited by 109
Effect of mycophenolate sodium in scleroderma-related interstitial lung disease
Simeón‐Aznar, C. P., Fonollosa‐Pla, V., Tolosa-Vilella, C., Selva-O’Callaghan, A., Solans, R., & Vilardell, M. (2011) · Clinical Rheumatology · doi:10.1007/s10067-011-1823-1 · Cited by 72
Cited by
Tashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,078
Self-citationRheumatoid arthritis-associated lung disease
Shaw, M., Collins, B. F., Ho, L. A., & Raghu, G. (2015) · European Respiratory Review · doi:10.1183/09059180.00008014 · Cited by 366
George, P. M., Spagnolo, P., Kreuter, M., Altinisik, G., Bonifazi, M., Martinez, F. J., Molyneaux, P. L., Renzoni, E. A., Richeldi, L., Tomassetti, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30355-6 · Cited by 349
Management of interstitial lung disease associated with connective tissue disease
Mathai, S. C., & Danoff, S. K. (2016) · BMJ · doi:10.1136/bmj.h6819 · Cited by 328
Kadura, S., & Raghu, G. (2021) · European Respiratory Review · doi:10.1183/16000617.0011-2021 · Cited by 328
Metadata
- Authors
- Fischer, A., Brown, K. K., Du Bois, R. M., Frankel, S. K., Cosgrove, G. P., Fernandez-Perez, E. R., Huie, T. J., Krishnamoorthy, M., Meehan, R. T., Olson, A. L., Solomon, J. J., & Swigris, J. J.
- Venue
- The Journal of Rheumatology
- Publisher
- The Journal of Rheumatology
- Published
- 2013-03-01
- Volume
- 40
- Issue
- 5
- Pages
- 640-646
- ISSN
- 0315-162X (ISSN-L)
- 1499-2752
- OpenAlex
- W1966466614
- Cited by
- 397
- References
- 7
- FWCI
- 18.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease. https://app.cochat.ai/papers/10.3899/jrheum.121043
- The paper
- Fischer, A., Brown, K. K., Du Bois, R. M., Frankel, S. K., Cosgrove, G. P., Fernandez-Perez, E. R., Huie, T. J., Krishnamoorthy, M., Meehan, R. T., Olson, A. L., Solomon, J. J., & Swigris, J. J. (2013). Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease. The Journal of Rheumatology. https://doi.org/10.3899/jrheum.121043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
